PA5-37821

antibody from Invitrogen Antibodies

Targeting: PRKAA2 AMPK, AMPKa2, PRKAA

Western blot (Supportive data in Antibodypedia)

Immunohistochemistry (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-37821

Provider

Invitrogen Antibodies

Product name

Phospho-AMPK alpha-1,2 (Thr172) Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Synthetic peptide

Description

A suggested positive control for Western blot is C2C12 cells; suggested positive control for IHC is human lung carcinoma.

Reactivity

Human, Mouse, Rat

Host

Rabbit

Isotype

IgG

Vial size

100 µL

Concentration

1 mg/mL

Storage

-20°C

Western blot

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Western blot analysis of extracts from C2C12 cells treated with serum or calf intestinal phosphatase (CIP) using AMPK-alpha1/AMPK-alpha2 (pThr174/Thr172) polyclonal antibody (Product # PA5-37821).

Immunohistochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunohistochemical analysis of Phospho-AMPK alpha-1,2 (Thr172) in paraffin-embedded Human lung carcinoma tissue using Phospho-AMPK alpha-1,2 (Thr172) Polyclonal Antibody (Product # PA5-37821).

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

NULL

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Altered expression of target protein upon cell treatment demonstrates antibody specificity. Immunofluorescence analysis of Phospho-AMPK alpha-1 (Thr172) using Phospho-AMPK alpha-1,2 (Thr172) (Product # PA5-37821) shows induction of AMPK alpha-1 phosphorylation at Thr172 residue in A-431 cell line upon Metformin treatment.

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Fig 2 PI3K-1 and AMPK do not play a role in mutant-COMP mTORC1 signaling. Panel 1 shows results of resveratrol and Panel 2 shows metformin treatments. Each treatment group contained 10 mice. Growth plates at 4 weeks: Control ( A , D , G , J ), MT-COMP untreated ( B , E , H , K ), resveratrol (0.25 g/L of resveratrol in drinking water from birth to 4 weeks) ( C ), or metformin (0.5 mg/mL in drinking water from birth to 4 weeks) ( F , I , L ). Immunostaining of PI3K-I ( A - C ), human COMP ( D - F ), pAMPK ( G - I ), and phospho-S6 (pS6) ( J - L ) is shown. Bars = 100 mum.